NCT04203862

A Study of NPC-22 in Healthy Adult Males

A Phase 1 Single Ascending Dose Study of NPC-22 in Healthy Adult Males

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Nobelpharma · Industry
• Sex: Male
• Age: 20 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this trial is to examine the safety and pharmacokinetics of NPC-22 administered in a single ascending dose in healthy adult males.

Detailed description

The healthy adult males will be randomized into six arms, and will receive single dose of NPC-22 (five doses, placebo)

Conditions

• Healthy Adult Subjects

Interventions

Type	Name	Description
DRUG	NPC-22	Single administration of low dose NPC-22
DRUG	NPC-22	Single administration of low/middle dose NPC-22
DRUG	NPC-22	Single administration of middle dose NPC-22
DRUG	NPC-22	Single administration of middle/high dose NPC-22
DRUG	NPC-22	Single administration of high dose NPC-22
DRUG	NPC-22 Placebo	Single administration of NPC-22 Placebo

Timeline

• Start date: 2019-11-19
• Primary completion: 2020-02-04
• Completion: 2020-02-04
• First posted: 2019-12-18
• Last updated: 2020-08-06

Locations

1 site across 1 country: Japan